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ABSTRACT
Pancreatic cancer is one with high mortality cancer in the world. Ninety percent of pancreatic cancer is 
pancreatic adenocarcinoma. Various factors is associated with an increased risk of pancreatic cancer including 
age, sex, race, genetic, history of chronic pancreatitis, diabetes mellitus, gallstone, obesity, Helicobacter pylori 
infection, smoking, diet, and polution exposure. A lot of cases were diagnosed in late stadium due to non-specific 
early clinical symptoms, and also, until now, there is no examination tool that may screen pancreatic cancer 
in the earliest stage. Total surgery resection is the therapy of choice in the early stadium of pancreatic cancer, 
and other therapy modalities are chemotherapy, radiotherapy. Combination of these modalities is frequently 
used in order to increase the effectiveness of therapy. Mesothelin, a surface glycoprotein on normal mesothelial 
cells, is overexpressed in pancreatic cancer; therefore, although it is not a cancer specific antigen, it can be used 
in diagnostic and treatment of pancreatic cancer. Several studies about mesothelin application in pancreatic 
cancer have been performed; however, more studies are needed to improve the application of mesothelin on 
pancreatic cancer. 
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ABSTRAK
Kanker pankreas merupakan salah satu kanker dengan tingkat mortalitas yang tinggi di dunia. Sembilan 
puluh persen kanker pankreas merupakan adenokarsinoma pankreas. Berbagai faktor berhubungan dengan 
peningkatan risiko kanker pankreas antara lain usia, jenis kelamin, ras, genetik, riwayat penyakit pankreatitis 
kronis, diabetes mellitus, batu empedu, obesitas, infeksi Helicobacter pylori, merokok, pola makan, dan paparan 
polusi. Gejala klinis yang tidak khas menyebabkan banyak kasus terdiagnosis saat stadium lanjut. Selain itu 
belum ada pemeriksaan penunjang yang dapat menyaring kanker pankreas secara dini hingga saat ini. Pilihan 
terapi yang tersedia adalah bedah, kemoterapi, radioterapi dengan bedah reseksi total merupakan terapi kuratif 
utama. Kombinasi modalitas terapi tersebut sering digunakan untuk meningkatkan efektivitas terapi. Mesotelin, 
glikoprotein permukaan sel mesotelial, banyak diekspresikan pada kanker pankreas, meskipun bukan merupakan 
antigen spesifik kanker tetapi dapat digunakan dalam diagnostik dan tatalaksana kanker pankreas. Beberapa 
penelitian mengenai aplikasi mesotelin pada kanker pankreas telah dilakukan, tetapi penelitian lebih lanjut 
masih diperlukan dalam mengembangkan aplikasi mesotelin pada kanker pankreas.
Kata kunci: kanker pankreas, faktor risiko, terapi, mesotelin
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INTRODUCTION
Pancreatic cancer is one of the deadly cancers in 
the world. The statistics in the United States (US) in 
2007 showed that pancreatic cancer ranks fourth as 
a cause of cancer death in male and female. Five year 
survival rate of pancreatic cancer in the US, although 
showing an increase, but the lowest when compared 
with survival in other cancers, there are 3% (1975-
1977), 3% (1984-1986), 6% (1999-2005) on white 
race and 2% (1975-1977), 5% (1984-1986), 5% (1999-
2005) at the African American race. In the year 2010 
is estimated that there are 21,370 new cases of 
pancreatic cancer in male and 21,770 new cases in 
female, while the mortality rate is estimated at 18,770 
in male and 18,030 in female.1 In Japan, pancreatic 
cancer is the fifth largest cause of death for cancer, 
of which 70% are found more common in male than 
female.2 There is no much data on pancreatic cancer 
in Indonesia. A study in Semarang reported 53 cases 
of pancreatic cancer between the years 1997-2004.3 
According to statistics in Indonesia in 2004-2007, 
pancreatic cancer is not included in the top 10 cancers.4
The high mortality rate of pancreatic cancer 
may due to no typical early symptoms; moreover, 
the cancer is rapidly spread to the lymphatic system 
and distant organs. Therefore, 80% of patients have 
already had locally advanced stage or metastases when 
the diagnosis is established. Consequently, curative 
therapy is more difficult in this condition. In addition, 
80 % of patients experience recurrence after curative 
surgery in the first 2 years.5,6,7
ETIOLOGY AND PATHOGENESIS
Histologically, pancreatic cancer can be derived 
from exocrine or endocrine pancreatic tissue. 
The majority (90%) of pancreatic cancer originates 
from the exocrine tissue of pancreatic ductal 
adenocarcinoma.3,8 Approximately, 70% of pancreatic 
cancers occur in the head of the pancreas, 20% in 
the body, and 10% in the tail of the pancreas.3,9 
The term pancreatic cancer used in this article is 
referred to exocrine pancreatic cancer tissue.
The main etiology of pancreatic cancer is still 
being studied until now, but several factors may 
increase the risk of pancreatic cancer, which is an 
interaction between exogenous and endogenous 
factors. Exogenous risk factors are smoking, diet, 
exposure to pollution; while the endogenous risk 
factors are age, sex, race, genetics, history of chronic 
pancreatitis disease, diabetes mellitus, gallstones, 
obesity, gastric infection by Helicobacter pylori 
(H. pylori).3,9,10
Smoking is the greatest risk factor for pancreatic 
cancer. The result of meta-analysis of 82 studies 
published between 1950 and 2007 showed that active 
smokers had an increased risk of pancreatic cancer 
about 1.74 times (95% CI = 1.61-1.87), while it 
was about 1.2 times (95% CI = 1.11-1.29) in former 
smokers. This risk lasted at least 10 years after one 
stopped smoking.11 A prospective cohort study in Japan 
showed a correlation between smoking and increase of 
mortality due to pancreatic cancer in male and female 
with relative risk of 1.8 (95% CI = 1.3-2.4).12 
Food consumption plays a role as a risk factor for 
pancreatic cancer. The study by Morales et al showed 
that people consuming milk or milk products every 
day had a tendency of suffering exocrine pancreatic 
cancer with 5 times greater of K-Ras mutation [odds 
ratio (OR) = 5.10; p = 0.04]. In addition, K-ras 
mutation also occured in people who had low intake 
of polyunsaturated fatty acids (PUFAs), omega-3 and 
vitamin E.2,13 High meat consumption is associated 
with increased risk of pancreatic cancer by 26% (95% 
CI = 1.02-1.56). Risk of pancreatic cancer is mainly 
on the consumption of red meat and processed meat 
at high temperatures.14
Exposure to certain substances in the environment is 
associated with the risk of pancreatic cancer. Exposure 
to benzene is significantly associated with mutations 
in K-ras gene (OR = 7.07; p < 0.05). Moreover, 
hydrocarbon exposures are strongly associated with 
mutation codon 12 from glycine into valine or aspartic 
acid on K-ras gene.15
Factors of age, sex, and race are reflected in 
epidemiological data of pancreatic cancer. Pancreatic 
cancer is rarely found at age < 50 years. Data in 
the United States in 2007 showed that pancreatic 
cancer is the largest cause of death in male and female 
patients aged > 40 years, with the highest rate in the 
age group of 60-79 years.1 The number of deaths due 
to pancreatic cancer in the US are more in male than 
female, while the incidence of pancreatic cancer is 
a little more common in female than male. In Japan, 
however, the data of pancreatic cancer incidence rate 
in male is higher than female, which is 17.7 : 14.0.1,16 
In this case, the role of hormonal factors in pancreatic 
cancer is still under study.17 Race-related factors in 
the pancreatic cancer are seen in the molecular 
differences between races. K-ras mutation into valine 
is more common in Afro-Americans (58%) than 
Caucasians (22%) with p = 0.015.2,18
Genetic predisposing factors play a role in 
10% of patients with pancreatic cancer. The most 
common disorder is the BRCA2 gene mutation. 
Abnormalities of chromosomes, such as the hereditary 
nonpolyposis colon cancer (HNPCC), familial atypical 
malignant melanoma syndrome (FAMMM), hereditary 
pancreatitis, are associated with an increased risk of 
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as tumor markers of carcinoembryonic antigen (CEA), 
carbohydrate antigen (CA 19-9), ultrasonography, 
computed tomography (CT), endoscopic retrograde 
cholangio-pancreaticography (ERCP), magnetic 
resonance image (MRI), and positron emission 
tomography (PET) scans.
CEA is a glycoprotein with high-molecular weight 
that is normally found in fetal tissue. In pancreatic 
cancer, there is an increase of CEA, but it may also 
be found in other organ cancers. Therefore, CEA is 
not a specific marker for pancreatic cancer.3 CA 19-9 
is one marker for pancreatic carcinoma that is widely 
used today. CA 19-9 examination is an examination 
of monoclonal antibodies against antigens that 
are normally found in circulating mucin in cancer. 
Elevated CA 19-9 level may also occur in other 
gastrointestinal adenocarcinoma such as cirrhosis 
as well as inflammation of the bile duct and liver.3,9 
The normal range limit of CA 19-9 depends on 
the intended use. To differentiate benign or malignant 
tumor, The European Group on Tumor Markers 
(EGTM) suggests the normal range limit of 37 kU/L.23 
However, The American Society of Clinical Oncology 
(ASCO) in 2006 did not recommend CA 19-9 as 
a screening test for pancreatic cancer since its specificity 
and sensitivity are not sufficient for screening, 
especially in early stages.24 To monitor therapeutical 
response and recurrence after surgical treatment, 
chemotherapy or radiation, ASCO recommends 
imaging test and biopsy in addition to CA 19-9.23,24
Currently, there are several options of imaging 
modalities for pancreatic cancer. Bipat et al in 
a meta-analysis of data in 1990-2003 on imaging 
modalities for pancreatic cancer suggested that for 
diagnosis, the sensitivity of helical CT, conventional 
CT, MRI, ultrasound were 91%, 86%, 84% and 76%, 
respectively; while the specificity were 85%, 79%, 
82%, 75%, respectively. For the determination of 
resectability, the sensitivity of helical CT, conventional 
CT, MRI, ultrasound were 81%, 82%, 82%, 83%, 
respectively and the specificity were 82%, 76%, 
78%, 63%.25 Transcutaneous abdominal ultrasound 
is useful in for initial screening, especially in 
patients who come with obstructive jaundice. 
Endoscopic ultrasonography is useful to overcome 
the air resistance on the gastrointestinal tract, which 
occurs in transcutaneous ultrasound and at the same 
time, it may collect the tissue specimens.3,26 CT scan 
is one of the initial imaging modalities for pancreatic 
cancer that can produce detailed images, especially 
as technology has been advanced to triple-phase 
contrast-enhanced CT.26,27 ERCP is very sensitive to 
detect abnormalities of biliary duct as well as useful 
channel for installing the bile drainage stent.3,26 MRI 
pancreatic cancer.2,3 History of chronic pancreatitis 
disease is associated with pancreatic cancer. In 1993, 
Lowenfels et al conducted a multicenter study using 
historical cohort design of 2,015 patients with chronic 
pancreatitis showing pancreatic cancer incidence ratio 
of 26.3 (95% CI = 19.9-34.2), and the risk increased 
together with the duration of pancreatitis, i.e. 1.8% 
after 10 years and 4% after 20 years being diagnosed.19
There is a correlation between diabetes mellitus 
and the occurrence of pancreatic cancer. Lin et al 
performed a large-scale prospective cohort study and 
found that the risk of pancreatic cancer increased in 
male having a history of diabetes mellitus with risk 
ratio (RR) = 2.12; 95% CI = 1.19-3.77. Moreover, 
the study also suggested that a history of gallstones 
or cholecystitis was associated with increased risk 
of pancreatic cancer deaths in female with RR = 
2.51; 95% CI = 1.41-4.46.20 A case-control study 
conducted by Li et al showed that overweight at age of 
14-39 years (body mass index (BMI) = 25 - 29.9 kg/
m2) and obesity at age 20-49 years (BMI ≥ 30 kg/m2) 
increased the risk of pancreatic cancer respectively 
1.67 times and 2.58 times, regardless whether 
the subject suffered from diabetes mellitus. There was 
also a stronger correlation in male than female subjects 
and in smokers than non smokers.21 The presence 
of H. pylori gastric infection with CAG+ strains 
causing peptic ulcers and gastric cancer may also be 
associated with the risk of pancreatic adenocarcinoma. 
Stolzenberg-Solomon et al in the case-control study in 
Finland found that subjects with serological H. pylori 
positive had an increased risk of pancreatic cancer (OR 
2.87; 95% CI = 1.05-3.34).22
CLINICAL MANIFESTATIONS
Early symptoms of pancreatic cancer are not 
typical; therefore, most cases have already been at 
advanced stage at the time the cancer is diagnosed. 
Initial complaint is not typical such as nausea, 
vomiting, bloating, steatorrhea. The three main 
complaints are abdominal pain that may spread to 
back, weight loss > 75%, jaundice due to biliary 
tract obstruction, with 80-90% cases are carcinoma 
of pancreatic head. In addition, Courvoisier sign 
may also be found in obstruction case due to head 
cancer of the pancreas, glucose intolerance, vein 
thrombosis, migratory thrombophlebitis or Trousseau 
sign, periumbilical nodules or Sister Mary Joseph’s 
nodule, hepatosplenomegaly, gastrointestinal bleeding 
and ascites.3,9
LABORATORY AND IMAGING TESTS
Nowadays, there are some laboratory and imaging 
tests supporting the diagnosis of pancreatic cancer, such 
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has advantages in imaging of pancreatic duct and can 
differentiate pancreatic cancer with inflammation and 
cystic lesions.3,9,26,28
STAGING AND MANAGEMENT
Management of pancreatic cancer currently has 
3 modalities of therapy, i.e. surgery, chemotherapy 
and radiotherapy. The options of currative 
surgical resection for pancreatic cancer include 
pancreaticoduodenectomy (Whipple procedure), 
distal pancreatectomy, and total pancreatectomy. 
Total pancreatectomy is the most effective therapy, but 
can only be applied to about 10-20% of cases only, 
which have no evidence of metastasis found on chest 
X-ray examination and abdominal-pelvic CT scan. 
Metastases have occurred in the majority of cases of 
pancreatic cancer when the diagnosis is established, 
i.e. 40% have been at locally advanced stage, either 
resectable or not (there is involvement of superior 
mesenteric artery, superior mesenteric vein, celiac axis, 
inferior vena cava and aorta); 40% had experienced 
visceral metastases. However, the 5-year-survival rate 
after total resection is only 10%. Adjuvant therapy can 
be given before or after surgery, which aims to shrink 
the tumor size so that ease the process of surgery and 
the treatment of micro metastasis. Optional available 
modalities may include chemoradiotherapy, which is 
usually applied in the case of advanced local stage, and 
chemotherapy, as well as the cases with metastasis.9,28
Chemotherapy in cases of widespread metastases 
has provided less satisfactory results. Two major 
chemotherapeutic agents that have been frequently 
used are 5-fluorouracil (5-FU) and gemcitabine. 5-FU 
is a pyrimidine analogue which can inhibit the synthesis 
of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA). Gemcitabine is an antimetabolite analogue 
deoxycytidine. Currently, gemcitabine is the standard 
chemotherapy of choice for pancreatic cancer. It is 
supported by a phase III clinical study comparing 5-FU 
with gemcitabine. The study demonstrated clinical 
response improvement (degree of pain, body weight, 
Karnofsky performance) 4.8% in 5-FU and 23.8% 
in gemcitabine (p = 0.0022); the survival rates were 
4.41 months and 5.65 months in 5-FU and gemcitabine, 
respectively.29 The combined use of chemotherapeutic 
agents has been extensively studied nowadays in order 
to improve the therapeutical response. Combination of 
four chemotherapeutic agents, i.e. cisplatin, epirubicin, 
gemcitabin, and 5-FU, showed median survival of 
10 months in a phase II study of patients with pancreatic 
adenocarcinoma.30
The  use  of  combinat ion  chemotherapy 
agents will certainly increase toxicity, especially 
hematologic and gastrointestinal systems.31 Combined 
chemoradiotherapy can be applied, particularly for 
cases without metastases. The given chemotherapy 
agent will increase tumor sensitivity to radiotherapy. 
However, whether chemoradiotherapy may improve 
survival of patients with pancreatic cancer remains 
to be investigated further, because few studies currently 
have provided different results.3,32 In addition, palliative 
symptomatic therapy is often administered, considering 
that the majority of patients have already been at 
advanced stage when the diagnosis is established, 
with the most common complaints are pain and 
jaundice.32
MESOTHELIN AND ITS APPLICATION ON 
PANCREATIC CANCER
Mesothelin is a glycoprotein which is expressed on 
normal mesothelial cells lining the pleura, pericardium, 
and peritoneum. Mesothelin gene encodes a 71-kDa 
precursor which is then processed into a 40-kDa 
mesothelin protein and 31-kDa megakaryocyte 
potentiating factor. Mesothelin is redundantly 
expressed by some tumors such as pancreas, lung, and 
ovary; therefore, although it is not a cancer specific 
antigen, its abnormal expression may be applied in 
pancreatic cancer.33,34 A study by Argani et al using 
serial analysis of gene expression (SAGE) found 
mesothelin mRNA expression (confirmed by in situ 
hybridization methods, RT-PCR) and mesothelin 
protein (confirmed by immunohistochemical methods) 
in pancreatic cancer. Both of the mesothelin mRNA 
expression and mesothelin protein were absent in 
normal pancreas.35 Li et al also found that mRNA 
expression increased 17.5 times in pancreatic cancer 
Table 1. Staging of exocrine pancreatic carcinoma3,28
M0 M1
N0 N1*
T in situ Stage 0
T1 (≤ 2 cm), limited to the pancreas Stage I
T2 (> 2 cm), limited to the pancreas
T3 (extends beyond the pancreas, but without involvement of the 
superior mesenteric artery or celiac axis)
Stage IIA Stage IIB
Stage IV
T4 (extends to the superior mesenteric artery, axis celiac, stomach, 
spleen, colon) 
Stage III
*N1 there has been metastases to regional lymph nodes
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tissue compared to the adjacent healthy pancreas 
tissue.36 Therefore, mesothelin has a potency to be used 
as a marker in supporting the diagnosis of pancreatic 
adenocarcinoma. 
Excessive expression of the mesothelin in 
pancreatic cancer can be used as a target-specific 
antibody therapy since mesothelin can stimulate 
the formation of monoclonal antibody. One study that is 
being developed is antimesothelin immunotoxin SS1P 
against solid cancers expressing mesothelin, such as 
pancreas. Hassan et al and Kreitman et al had conducted 
the phase I study on antimesothelin immunotoxin 
evaluating the dose and route of administration, 
either by bolus injection or by continuous intravenous 
infusion.37,38 However, there has been only little number 
of pancreatic cancer patients examined in both studies; 
respectively 2 and 1 subjects since both studies also 
evaluated other cancers that also express mesothelin 
(i.e. mesotheliomas and ovarian). Therefore, further 
studies are necessary.37,38 Combination of SS1P therapy 
with other therapeutic modalities is also possible. 
The increase of mesothelin expression is found on 
cell surfaces after being irradiated, and it will increase 
the sensitivity of cancer cells against SS1P. Such 
mechanism may explains the benefit of combining 
SS1P therapy with radiotherapy.39
Another potency of mesothelin that can be developed 
is a therapeutic vaccine for cancer. Vaccination with 
virus like particle (VLP) can increase the concentration 
of specific antibodies and CD8+ responses. These, 
may inhibit tumor progression in C57BL/6J mice and 
increase the specific antibody against mesothelin.36
CONCLUSION
Pancreatic cancer is one of the deadly cancers in 
the world. It is often diagnosed lately at advanced 
stage due to no typical early symptoms of the cancer. 
Moreover, no screening test having a good sensitivity 
to detect the cancer at early stage is available until now. 
The most effective curative treatment is total 
resection; however, the survival rate after total 
resection is still quite low and only few patients could 
have total resection. Combination therapies with other 
therapeutic modalities have not provided satisfactory 
results. Further studies to find a more sensitive and 
specific diagnostic tool as well as the more effective 
treatment modalities for pancreatic cancer are 
necessary. Mesothelin, a glycoprotein which is widely 
expressed in pancreatic cancer, has a good potency to 
be used in diagnosis and treatment of pancreatic cancer.
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